This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pharma cartel, market abuses call for easier China market access to bolster competition, cabinet advisor says

By MLex Staff ( May 30, 2023, 07:27 GMT | Insight) -- China should consider easing access to its markets for active pharmaceutical ingredients to bolster competition, an antitrust advisor to the country's cabinet said. The remarks came after two drug makers were slapped with penalties totaling 320 million yuan ($45 million) for anticompetitive conduct. The cases mark the latest in a series of actions by the State Administration for Market Regulation against API suppliers.China should consider easing access to its markets for active pharmaceutical ingredients, or API, to bolster competition, an antitrust advisor to the country's cabinet said....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections